Recent developments and highlights in rhinitis and allergen immunotherapy
S Reitsma, S Subramaniam, WWJ Fokkens, DY Wang - Allergy, 2018 - Wiley Online Library
This review paper aims to provide an overview of recent developments in the field of allergic
and non‐allergic rhinitis, as well as allergen immunotherapy. Recent advances in …
and non‐allergic rhinitis, as well as allergen immunotherapy. Recent advances in …
The Use of Azelastine Hydrochloride/Fluticasone Propionate in the Management of Allergic Rhinitis in Asia: A Review
P Tantilipikorn, V Kirtsreesakul, C Bunnag… - Journal of Asthma …, 2024 - Taylor & Francis
The incidence of allergic rhinitis (AR) in Asia and the world is steadily rising. Patients
experience incomplete symptom relief despite existing treatment options, which warrants the …
experience incomplete symptom relief despite existing treatment options, which warrants the …
Focused allergic rhinitis practice parameter for Canada
Allergic rhinitis (AR) is a prevalent disease in Canada that affects both children and adults.
Several guidelines for the management of AR have been published by professional allergy …
Several guidelines for the management of AR have been published by professional allergy …
[HTML][HTML] Efficacy of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, delivered in a single spray, for the treatment of seasonal …
NI Ilyina, AS Edin, NG Astafieva, AS Lopatin… - … Archives of Allergy and …, 2019 - karger.com
Background: The novel intranasal formulation of azelastine hydrochloride (AZE) and
fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line …
fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line …
Real‐life effectiveness of MP‐AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy
R Kaulsay, DT Nguyen, HC Kuhl - Immunity, Inflammation and …, 2018 - Wiley Online Library
Introduction Most allergic rhinitis (AR) patients have moderate‐to‐severe, persistent
disease. Meda Pharma's AzeFlu (MP‐AzeFlu) combines intranasal azelastine hydrochloride …
disease. Meda Pharma's AzeFlu (MP‐AzeFlu) combines intranasal azelastine hydrochloride …
Dendritic cell‑CD4+ T cell interaction: The differential role of IL‑4/IL‑13 in serum IgE levels in house dust mite allergic patients
LD Cernescu, L Haidar… - Experimental and …, 2021 - spandidos-publications.com
Allergic asthma is a chronic airway inflammatory disorder triggered by inhalant allergens.
Interleukin (IL)‑4 and IL‑13 play a main role in the generation of T helper cell type 2 (Th2) …
Interleukin (IL)‑4 and IL‑13 play a main role in the generation of T helper cell type 2 (Th2) …
Real-Life Effectiveness of MP-AzeFlu (Dymista®) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale
P Stjärne, DT Nguyen, HC Kuhl - Pragmatic and Observational …, 2023 - Taylor & Francis
Background Many allergic rhinitis (AR) patients have moderate/severe persistent disease.
MP-AzeFlu (Dymista®) comprises intranasal azelastine hydrochloride and fluticasone …
MP-AzeFlu (Dymista®) comprises intranasal azelastine hydrochloride and fluticasone …
[PDF][PDF] Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis
WE Berger, TB Mustakov, TZ Kralimarkova… - Allergy Asthma …, 2020 - researchgate.net
Background: Allergic rhinitis (AR) is the most common chronic noncommunicable disease
worldwide that affects any age during the human life span but raises particular concerns …
worldwide that affects any age during the human life span but raises particular concerns …
[HTML][HTML] Atopy and lifestyle survey of allergic patients from urban environment in Romania: preliminary data from an interactive qualifying project
PM Leru, D Kay, J Kelly, T Tuong, T Schaeffer… - Cureus, 2021 - ncbi.nlm.nih.gov
Methods The study is based on the cooperation Interactive Qualifying Project (IQP) called
“Pollen Allergies in Romania: Optimizing Data Analysis in Raising Awareness”, agreed and …
“Pollen Allergies in Romania: Optimizing Data Analysis in Raising Awareness”, agreed and …
An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu® in Austrian Patients with Persistent Allergic Rhinitis
K Marth, A Renner, G Langmayr, W Pohl… - Drugs-Real World …, 2024 - Springer
Background Many patients with allergic rhinitis (AR) have moderate-to-severe persistent AR.
Meda Pharma's AzeFlu (MP-AzeFlu®) is an intranasal AR treatment comprising a novel …
Meda Pharma's AzeFlu (MP-AzeFlu®) is an intranasal AR treatment comprising a novel …